Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CA
Cabaletta Bio, Inc. Common Stock
CABA
Mkt Cap
$239.9M
Volume
5.84M
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CA
CABA
CA
Cabaletta Bio, Inc. Common Stock
CABA
News
·
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight
Mkt Cap
$262.8M
Volume
5.84M
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight
The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.
GlobeNewswire Inc. · Sep 14, 2026
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
Cabaletta Bio announces positive clinical data for its rese-cel therapy in patients with myositis, lupus, and scleroderma, with most patients achieving clinically meaningful responses while off immunomodulators and steroids. The company plans to initiate registrational trials and engage with the FDA on regulatory pathways.
GlobeNewswire Inc. · Jun 11, 2025
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Cabaletta Bio announced plans to submit a Biologics License Application (BLA) for its rese-cel therapy in myositis by 2027, following recent alignment with the FDA on registrational cohorts for the RESET-Myositis trial. The company also received Regenerative Medicine Advanced Therapy (RMAT) designation for rese-cel in myositis.
GlobeNewswire Inc. · May 29, 2025
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
Cabaletta Bio, a clinical-stage biotechnology company, announced that it will participate in a fireside chat at Guggenheim's SMID Cap Biotech Conference on February 5, 2025. The company is focused on developing curative targeted cell therapies for autoimmune diseases.
GlobeNewswire Inc. · Jan 29, 2025
US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode
US stock futures are pointing to a higher open on Friday as investors look to end November on a positive note. Analysts suggest that December has historically been a strong month for markets, with only one instance of it being the worst month in the last 95 years.
Benzinga · Nov 29, 2024
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio, a clinical-stage biotechnology company, announced its participation in several investor conferences in September 2024, including the Morgan Stanley, Wells Fargo, H.C. Wainwright, and Cantor Fitzgerald conferences.
GlobeNewswire Inc. · Aug 28, 2024
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 –
GlobeNewswire Inc. · Jun 14, 2024
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials –
GlobeNewswire Inc. · May 15, 2024
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 9:30 a.m. ET in New York, NY.
GlobeNewswire Inc. · May 13, 2024
Wall Street Breakfast: The Week Ahead
Discover the upcoming events and earnings reports in the financial market, including notable companies like Disney, Tyson Foods, and Uber.
Seeking Alpha · May 5, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CA
CABA
Cabaletta Bio, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
CABA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CABA yet.
Related Tickers
Earnings